A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Olezarsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Registrational; Therapeutic Use
- Acronyms BALANCE
- Sponsors Ionis Pharmaceuticals
- 07 Apr 2024 According to an Ionis Pharmaceuticals Media Release, company will host webcast on Monday, April 8 at 10:00 am ET t to discuss the detailed results from the Balance study.
- 07 Apr 2024 According to an Ionis Pharmaceuticals Media Release, based on the results of this study company is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.
- 07 Apr 2024 According to an Ionis Pharmaceuticals Media Release, results of this study were presented at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The New England Journal of Medicine (NEJM).